Mayinglong Pharmaceutical Group Co., LTD.

Shanghai Stock Exchange 600993.SS

Mayinglong Pharmaceutical Group Co., LTD. EBIT for the year ending December 31, 2023: USD 76.50 M

Mayinglong Pharmaceutical Group Co., LTD. EBIT is USD 76.50 M for the year ending December 31, 2023, a -6.78% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Mayinglong Pharmaceutical Group Co., LTD. EBIT for the year ending December 31, 2022 was USD 82.07 M, a -3.74% change year over year.
Mayinglong Pharmaceutical Group Co., LTD. EBIT for the year ending December 31, 2021 was USD 85.26 M, a 12.21% change year over year.
Mayinglong Pharmaceutical Group Co., LTD. EBIT for the year ending December 31, 2020 was USD 75.98 M, a 25.02% change year over year.
Mayinglong Pharmaceutical Group Co., LTD. EBIT for the year ending December 31, 2019 was USD 60.78 M, a 136.73% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shanghai Stock Exchange: 600993.SS

Mayinglong Pharmaceutical Group Co., LTD.

CEO	Mr. Youzhang Xia
IPO Date	May 17, 2004
Location	China
Headquarters	100 Zhoujia Wan
Employees	2,882
Sector	Health Care
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies

Description

Mayinglong Pharmaceutical Group Co., LTD. engages in the manufacture, wholesale, and retail of pharmaceutical products primarily in China. It offers hemorrhoid, gynecological, cough, skin, functional food, and Chinese medicine drink tablet products, as well as medical devices. The company also sells its products online. It also operates hospitals. Mayinglong Pharmaceutical Group Co., LTD. was founded in 1582 and is based in Wuhan, China.

Key trends

Past 5 years